TGF-β1-mediated repression of SLC7A11 drives vulnerability to GPX4 inhibition in hepatocellular carcinoma cells

摘要

TGF-β1 was administered to PLC/PRF/5, Huh7, Huh6, HepG2, SNU387, SNU449, SNU475, and SK-Hep1 cells at a concentration of 5 ng/mL and cell viability was measured using the CellTiter Glo® assay after 6 days; three independent experiments were performed in triplicate. TGF-β1 was applied to PLC/PRF/5 (  = 4), Huh7 (  = 3), Huh6 (  = 4), HepG2 (  = 4), SNU387 (  = 3), SNU449 (  = 3), SNU475 (  = 3), and SK-Hep1 (  = 3) cells for 24 or 48 h at a concentration of 5 ng/mL, and then whole-cell lysates were assessed with western blot analyses. Representative images are shown. PLC/PRF/5 (  = 5), Huh7 (  = 7), Huh6 (  = 3), and HepG2 (  = 3) cells were treated with 5 ng/mL of TGF-β1 for 24 h and then collected for RT-PCR analyses to detect the mRNA levels of xCT, vimentin, and β-actin; vimentin was used as a positive TGF-β1-responsive gene. All data are expressed as the mean ± SD.  **